Navigation Links
ArunA Biomedical Names Harold Ingalls to its Board of Directors
Date:9/9/2008

ATHENS, Ga., Sept. 9 /PRNewswire/ -- ArunA Biomedical, Inc., the first company to commercialize human embryonic stem cell derived products and services, announced today the appointment of former Serologicals Corporation CFO, Harold "Bud" Ingalls, to its Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

Mr. Ingalls brings over 40 years of financial leadership, including nearly 20 years of experience as a chief financial officer to ArunA's Board. Prior to his current role as CFO of Premier Exhibitions, Mr. Ingalls served as Vice President and Chief Financial Officer at CardioMEMS, where he played a key role in the organization's transformation. During his tenure at CardioMEMS, Mr. Ingalls led the completion of two private financing rounds totaling over $45 million with venture capitalists and strategic investors. From 2001 to 2006, he held the position of Vice President of Finance and Chief Financial Officer of Serologicals Corporation. Under Mr. Ingalls' leadership, Serologicals' enterprise value increased by nearly $1.0 billion, as the result of strong organic growth, successful acquisitions and stringent cost control. Prior to his work with Serologicals, Mr. Ingalls was employed as President and Chief Financial Officer of LaRoche Industries, Inc. Mr. Ingalls is a member of the American Institute of Certified Public Accountants and received a BBA degree in Accounting from the University of Wisconsin.

"We are pleased to welcome Bud to the ArunA Board. His domain knowledge and impressive combination of strategic and financial expertise in the life sciences industry will be a tremendous asset to ArunA Biomedical as we move forward in our next phase of growth," said ArunA President and CEO, William T. Sharp.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.

For more information, visit: http://www.arunabiomedical.com


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
2. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
3. Creator of PubMed Central biomedical research database recognized for outstanding citizen service
4. Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion
5. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant
6. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
7. The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere
8. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
9. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education
11. Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten Seed ... The seed processing plant opened in Marshallville in 2006, and a bagging and shipping ... opportunity for transition of Patten Seed operations to the Middle Georgia location from their ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium ... providers and offered an opportunity to collaborate and network with healthcare colleagues across the ... attendees gathered for a lively discussion on trends and issues that healthcare leaders will ...
(Date:3/28/2017)... California (PRWEB) , ... March 28, 2017 , ... Bacteria and fungi are probably not ... microorganisms are bad. In fact, including the right microorganisms in your diet can actually improve ... favorite foods. , This is the topic of a new peer-reviewed paper ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... custom smile makeovers without requiring a referral. Trimble Dental offers a ... treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or missing ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  A new ... (AADE) found that Medicare,s Competitive Bidding Program (CBP) significantly ... testing supplies. The lack of choice forces beneficiaries to ... have dire health consequences. AADE,s survey ... by AADE and others pointing out the inherent problems ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... , March 27, 2017  BERG, a ... data-driven, biological research approach, today announced that ... the discovery of new data using a ... brown fat metabolism. Joslin Diabetes Center led ... Biology┬« platform for analysis of samples.  The ...
Breaking Medicine Technology: